Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vir Biotechnology ( (VIR) ) has shared an announcement.
On February 25, 2026, Vir Biotechnology, Inc. entered into an underwriting agreement with a syndicate of investment banks to offer 17,647,059 shares of its common stock at $8.50 per share. The transaction, conducted under an effective shelf registration with the U.S. Securities and Exchange Commission, is expected to close on February 27, 2026, subject to customary conditions.
The company granted underwriters a 30-day option to purchase up to an additional 2,647,058 shares at the same public offering price and anticipates net proceeds of about $141.1 million, or $162.3 million if the option is fully exercised. The capital raise is poised to strengthen Vir Biotechnology’s balance sheet and provide additional financial flexibility for its operations and pipeline in the competitive infectious disease therapeutics market.
The most recent analyst rating on (VIR) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.
Spark’s Take on VIR Stock
According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.
The score is lifted by strong, improving catalysts from the latest earnings call (Astellas partnership terms, extended cash runway, and encouraging early clinical data with a defined development plan) and supported by bullish technical trend signals. It is held back primarily by weak financial performance (continued large losses and cash burn with volatile, milestone-driven revenue) and a negative P/E that underscores ongoing unprofitability.
To see Spark’s full report on VIR stock, click here.
More about Vir Biotechnology
Vir Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for serious infectious diseases. The company operates in the U.S. healthcare and life sciences sector, using advanced technologies to address unmet medical needs in viral infections and related conditions.
Average Trading Volume: 2,748,389
Technical Sentiment Signal: Buy
Current Market Cap: $1.32B
Find detailed analytics on VIR stock on TipRanks’ Stock Analysis page.